DAWSON JAMES SECURITIES

Member FINRA/SIPC

DAWSON JAMES SMALL CAP GROWTH CONFERENCE

Monday–Tuesday, October 29–30, 2018

Wyndham Grand Jupiter
at Harbourside Place
Jupiter, Florida

WE THANK OUR SPONSORS FOR THEIR SUPPORT

Schiff Hardin

Ellenoff Grossman & Schole LLP

M2 COMPLIANCE

MARCUM ACCOUNTANTS ▲ ADVISORS

SheppardMullin

SICHENZIA ROSS FERENCE LLP

Nasdaq

PitchBook

SNN Stock News Now The Official MicroCap News Source

WSR WallStreet Research Solutions for Emerging Companies

DAWSON JAMES SECURITIES

Member FINRA/SIPC

Dear Guests:

Welcome to the 4th Annual Dawson James 2018 Small Cap Growth Conference. We would like to thank you all for your participation and look forward to an exciting and productive day.

Dawson James is committed to providing Microcap and Small Cap companies with broad capital markets' distribution, insightful research and access to capital through innovative solutions including our Diversified Investor Offering™ utilizing our network of global institutional investors and broad-based retail platform.

This year we are pleased to have added two veteran research analysts to complement the efforts of Robert Wasserman, our Director of Research. Barry Sine has joined covering Technology, Media and Telecom (TMT) alongside of Carol Ann Werther in the biotech sector. We hope you find some time to meet with them today or visit the "Dawson James Research Table" to download copies of recent reports.

Our seasoned banking team has advised and assisted our clients with capital raising transactions including many of the companies you will meet today. The addition of Michael Rindos has added deeper coverage of the TMT sector. We anticipate continued strength and opportunity in the capital markets throughout the 4th Quarter.

Dawson James has significant expertise in working with OTC listed companies who are planning an up list to elevated exchanges with or without additional capital needs. We are pleased to highlight this process and various strategies today in our "Uplist Boot Camp" luncheon with our expert panelists and sponsors from Schiff Hardin, Marcum, Crescendo IR and Nasdaq.

We'd like to extend a special thank you to Jack Stover, CEO of Interpace Diagnostics for organizing and hosting the kick off panel discussing the "Impact of Bioinformatics on Precision Medicine". We're pleased to highlight this discussion by prominent industry leaders on breakthrough technologies and their impact on improving patient outcomes in clinical trials.

We would like to thank all our Sponsors: Schiff Hardin, Ellenoff Grossman & Schole, Sichenzia Ross Ference, M2 Compliance, Marcum LLP, Nasdaq, Crescendo IR, Sheppard Mullin Richter & Hampton, StockNewsNow, Pitchbook and WallStreet Research along with all our presenting companies for supporting Dawson James in our effort to bring innovative ideas and investors together at this exclusive event.

Enjoy the day from your Dawson James Family Team!

DAWSONJAMES SECURITIES

Dawson James Securities specializes in capital raising for small and microcap public and private growth companies primarily in the Life Science/Health Care, Technology and Consumer sectors and is a full service investment banking firm with research, institutional and retail sales, as well as execution trading and corporate services. According to Sagient Research Systems*, Dawson James has been ranked as a top Placement Agent in terms of aggregate PIPE and RD transactions cumulatively since 2005.

Dawson James utilizes a unique approach to financings using their trademarked DIO "Diversified Investor Offering™" which blends investor interest using a combination of retail clients and Institutional investors. Headquartered in Boca Raton, FL, Dawson James is privately held with offices in New York, Maryland and New Jersey. www.dawsonjames.com

Robert D. Keyser
Chief Executive Officer
Direct: 561-208-2910
bob@dawsonjames.com

Thomas W. Hands
President
Direct: 561-208-2913
thands@dawsonjames.com

R. Douglas Armstrong, Ph.D.
Chief Business Officer
Direct: 561-208-2990
darmstrong@dawsonjames.com

Carlo Corzine
Inv. Banking/Syndicate Principal
Direct: 561-208-2984
ccorzine@dawsonjames.com

David Weinstein
Mg. Ptr. – Investment Banking
Direct: 561-208-2935
dweinstein@dawsonjames.com

Michael Rindos
Mg. Dir. – Investment Banking
Direct: 646-465-6893
mrindos@dawsonjames.com

David Buchsbaum
Sr. VP-Investment Banking
Direct: 561-208-2938
dbuchsbaum@dawsonjames.com

Elise Stern
Mg. Dir. – Capital Markets
Direct: 561-208-2926
estern@dawsonjames.com

James Hopkins
VP – Capital Markets
Direct: 561-208-2964
jhopkins@dawsonjames.com

Michael Martini
Investment Banking Associate
Direct: 561-208-2932
mmartini@dawsonjames.com

Richard Aulicino
Ex. Dir. – National Sales Manager
Direct: 561-208-2952
raulicino@dawsonjames.com

Dawson James Securities, Inc.
Boca Raton, FL • New York, NY • Columbia, MD • Manasquan, NJ
Tel: 561-391-5555 • www.dawsonjames.com
Member FINRA/SIPC

CONTENTS

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.



For 30 years, the sophisticated investor has looked to WallStreet Research (WSR) to identify substantially undervalued small cap companies. Why? Consistent results. The industries and small cap stocks covered by our specialists consistently deliver significant price appreciation and increased trading volume. Widespread distribution adds to our effectiveness. WSR reports are circulated via our website and to a proprietary database of over 100,000 investors, as well as through major website portals including Bloomberg, AOL, Google and Yahoo. WSR also runs road shows and one-on-one meetings for companies in the New York, California and Florida markets and conducts CEO interviews at the NASDAQ and NYSE.

The in-depth investigative and analytical service that we provide is second to none. Please visit our website at www.WallStreetResearch.org to review our stellar track record, and see how our team of top-ranked CFA's, MBA's and seasoned analysts can enhance your shareholder value and liquidity.

PLEASE CONTACT:
Alan Stone - Managing Director @ WallStreet Research(WSR)
email: alanstone@wallstreetresearch.org
30W 44th St. New York, NY 10036 Also @
10940 Wilshire Blvd. Los Angeles, CA 90024
Tel. (310)909-4134 /Los Angeles or
Barbara J. Blake @ (415) 419-4239 email: bjblake1229@att.net
www.WallStreetResearch.org

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **Adial Pharmaceuticals**
Address: **1180 Seminole Trail, Suite 495, Charlottesville, VA 22902**
Exchange: **Nasdaq**
Symbol: **ADIL**

BUSINESS OVERVIEW

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug candidate, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking, and no overt safety concerns. The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.

MANAGEMENT

CEO: **William Stilley**
President: **William Stilley**
Chairman: **Bankole Johnson**
CFO: **Joseph Truluck**
Other Officers: **Tomaz Zastawny CDO**
Investor Relations Company Name: **Crescendo Communications**
Contact Person: **David Waldman**
Email address: **dwaldman@crescendo-ir.com** Telephone Number: **(917) 335-2239**

Year Ending December 31, 2017 (FY)		Year to Date 2018 at June 2018	
Revenues:	**$ Pre-Revenue**	Revenues:	**$ Pre-Revenue**
Earnings:	**$ (442,838)**	Earnings:	**$ (2,171,306)**
Cash on Hand:	**$ 18,248**	Cash on Hand:	**$ 150,026**
Debt:	**$ 1.032 M**	Debt:	**$ 350,000**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Large market with unmet need
- Late stage oral drug (Phase 3 ready)
- Companion diagnostic to identify responders
- Efficient path to regulatory approval
- Low cost manufacturing
- Licensed patent protection through 2032
- Indication expansion opportunities for AD04
- Raised $7.32 million in July 2018

KEY STATISTICS

as of 9/19/18 except as noted
Price as of 10/15/2018: **$2.56**
52 Week Range: **$2.51-$4.40**
Market Cap: **$19.7 M**
Shares O/S: **6.556 M**
Float (MM): **3.1 M**
Institutional Ownership %: **2.29%**
Avg. Volume: **29,862**
Institutional Ownership %: **12.8%**

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **Altimmune, Inc.**
Address: **910 Clopper Road, Ste 201S, Gaithersburg, MD 20878**
Exchange: **Nasdaq**
Symbol: **ALT**

BUSINESS OVERVIEW

Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of infectious disease. NasoVAX our influenza vaccine candidate has unique characteristics, stimulating multiple arms of the immune system that offer the potential to stop infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is a next-generation anthrax vaccine candidate that is intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.

MANAGEMENT

President & CEO: **William Enright**
Interim CFO: **Will Brown,** CPA, MBA
Executive Chairman: **Mitch Sayare,** PhD
Other Officers: **Dr. Sybil Tasker, CMO**
Investor Relations Company Name: **LifeSci Advisors**
Contact Person: **Ashley Robinson**
Email address: arr@lifesciadvisors.com
Telephone Number: **(617) 535-7742**

Year Ending December 31, 2017 (FY)		Year to Date 2018 thru 2Q	
Revenues:	**$10.7M**	Revenues:	**$5.1M**
Earnings:	**N/A**	Earnings:	**N/A**
Cash on Hand:	**$12.3M**	Cash on Hand:	**$4.8M**
Debt:	**$0**	Debt:	**$1.5M**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- $42M raised in 3 financings over the last 2 weeks
- Positive Ph2a NasoVAX clinical data presented at ID-Week
- Two-dose data from Ph1 NasoShield study expected 4Q18
- $2.5 M additional BARDA funding received Sept 2018

KEY STATISTICS

Price as of 10/15/2018: $**3.87**
52 Week Range: **$4.07–$94.81**
Market Cap: **$36M**
Shares O/S: **7.4M**
Float (MM): **7M**
Institutional Ownership %: **7%**
Avg. Volume: **572,000**

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **Biocept, Inc.**
Address: **5810 Nancy Ridge Dr., San Diego CA 92121**
Exchange: **Nasdaq**
Symbol: **BIOC**

Biocept
Completing the Answer™

BUSINESS OVERVIEW

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

MANAGEMENT

CEO: **Mike Nall**
President: **Mike Nall**
Investor Relations Company Name: **LHA**
Contact Person: **Jody Cain**
Email address: **jcain@lhai.com**
Chairman: **David Hale**
CFO: **Tim Kennedy**
Telephone Number: (**310) 691-7107**

Year Ending December 31, 2017 (FY)		Year to Date 2018 (1H 2018)	
Revenues:	**$5.1M**	Revenues:	**$1.6M**
Earnings:	**-$21.6M**	Earnings:	**-$12.5**
Cash on Hand:	**$2.1M**	Cash on Hand:	**$2.6M**
Debt:	**$1.4M**	Debt:	**$1.3M**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Increase penetration into liquid biopsy market
- Enter into strategic partnerships (U.S. & Int'l)
- Validate NGS panel from Thermo Fisher in Lab
- Become Thermo Fisher LB Center of Excellence
- Sign new third party health plan contracts
- Publish and present additional clinical data
- Develop kit strategy

KEY STATISTICS

as of 10-08-18 except as noted
Price as of 10/15/2018: **$2.39**
52 Week Range: **$2.51–$39.6**
Market Cap: **$15M**
Shares O/S: **6M**
Float (MM): **3.5M**
Institutional Ownership: **12.8%**
Avg. Volume: **554,800**

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **Biofrontera AG**
Address: Hemmelrather Weg 201, 51377 Leverkusen Germany
Exchange: **Nasdaq** | ***FRA***
Symbol: **BFRA** | ***B8F***

Biofrontera
Experts in photodynamic therapy

BUSINESS OVERVIEW

Biofrontera (Nasdaq: BFRA) is an established commercial stage Biopharmaceutical Company specializing in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. The Company's lead product Ameluz is a topical prescription drug, in combination with medical device BF-RhodoLED, for photodynamic therapy (PDT). Ameluz is currently approved and launched for the treatment of mild to moderate Actinic Keratosis (AK) in the U.S., 13 EU countries and Switzerland. Ameluz is also approved in the EU for the treatment of Basal Cell Carcinoma and Ameluz in combination with Daylight PDT for the treatment of AK.

MANAGEMENT

CEO: **Dr. Hermann Lübbert**
Other Officers: **Christoph Dünwald, CCO**
Investor Relations Company Name: **The Ruth Group**
Contact Person: **Tram Bui**
Email address: **tbui@theruthgroup.com**
CFO: **Thomas Schaffer**
Telephone Number: (**646) 536-7037**

Year Ending December 31, 2017 (FY)		Year to Date 2018	
Revenues:	**€12M**	Revenues:	**€9M**
Earnings:	**€(0.42) per share**	Earnings:	**€(0.18) per share**
Cash on Hand:	**€11.1M**	Cash on Hand:	**€26.3M**
Debt:	**€12.4M ***	Debt:	**€13.0M ***

** = long-term debt including 10M draw down from EIB loan*

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Guidance: Revenue of 16 to 20 million euro for the full year 2018 and a net result for the year of between 15 and 16 million euro.
- Initiated patient recruitment for U.S. Phase III trial evaluating Ameluz for superficial basal cell carcinoma. Expect trial completion in 1H2020.
- Completed patient recruitment in EU phase III trial for treatment of actinic keratoses on the extremities as well as the trunk and neck. Expect trial completion in 1Q2019
- Completed initial public offering (IPO) of American Depositary Shares on the Nasdaq Capital Market in the U.S. and a preemptive rights offering in Germany of Biofrontera's ordinary shares, with aggregate net proceeds of €21.6 million
- Product-specific J-Code and revised CPT codes went into effect as of January 2, 2018 and will improve reimbursement for PDT prescribing physicians in the United States

KEY STATISTICS

BFRA | ***B8F***
Price as of 10/15/2018: **$13.30** | ***€5.89***
52 Week Range: **$11.25–$17.98** | ***€2.91–€6.10***
Market Cap: **$297M** | ***€268M***
Shares O/S: **44.5** | ***44.5***
Float (MM): **12.1M** | ***24.2M***
Institutional Ownership %: **0.23%** | ***35%***
Avg. Volume **7,114** | ***51,697***

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **BioSig Technologies Inc**
Address: **12424 Wilshire Blvd, Suite 745 Los Angeles, CA 90025**
Exchange: **Nasdaq**
Symbol: **BSGM**

BioSig™ technologies

BUSINESS OVERVIEW

BioSig Technologies, Inc. (Nasdaq: BSGM), is a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace. The PURE EP™ System from BioSig Technologies™ was designed to improve the clinical information for electrophysiology (EP) studies and cardiac catheter ablation – procedures to test the electrical activity of the heart to find where an abnormal heartbeat originates, and then is destroyed.

MANAGEMENT

CEO: **Ken Londoner**
President: **Ken Londoner**
Investor Relations Company Name: **BioSig Technologies Inc.**
Contact Person: **Josh Conroy**
Email address: **jconroy@biosigtech.com**
Chairman: **Ken Londoner**
CFO: **Steve Chaussy**
Telephone Number: **(917) 647-9502**

Year Ending December 31, 2017 (FY)		Year to Date 2018 (Q2 18)	
Revenues:	**$ 0**	Revenues:	**$ 0**
Earnings:	**$ (12,695,743)**	Earnings:	**$ (8,403,757)**
Cash on Hand:	**$ 1,547,579**	Cash on Hand:	**$ 3,673,137**
Debt:	**$ 0** (excluding AP, etc.)	Debt:	**$ 0** (excluding AP, etc.)

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- 10-Year Partnership with the Mayo Clinic (2017)
- FDA Approval (8/14/2018)
- Nasdaq Listed (10/20/2018)
- First Sales (2018)
- First in man data (2018/2019)
- Clinical Trials (2019)

KEY STATISTICS

Price as of 10/15/2018: **$4.80**
52 Week Range: **$3.21–$7.86**
Market Cap: **$8.96 Million**
Shares O/S: **14,937,957**
Float (MM): **9 Million**
Institutional Ownership %: **0**
Avg. Volume: **53.7 Million**

BioSig Technologies, Inc. had a last minute conflict and had to cancel presenting at this conference.

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **Champions Oncology, Inc.**
Address: **1 University Plaza Dr # 307, Hackensack, NJ 07601**
Exchange: **Nasdaq**
Symbol: **CSBR**

CHAMPIONS ONCOLOGY

BUSINESS OVERVIEW

Champions Oncology, Inc. is engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs.. The Company's Translational Oncology Solutions are used by pharmaceutical and biotechnology companies seeking personalized approaches to drug development, which can lower the cost and increase the speed of developing new drugs. For more information, please visit www.championsoncology.com.

MANAGEMENT

CEO: **Ronnie Morris,** MD
CMO: **Angela M. Davies,** MD, FRCP (C)
Investor Relations Company Name: **Hayden IR**
Contact Person: **James Carbonara**
Email address: **James@haydenir.com**
Chairman: **Joel Ackerman**
CFO: **David Miller**
Telephone Number: (**646) 755-7412**

12 months ended April 30, 2018		First Fiscal Quarter Ended July 31, 2018	
Revenues:	**$20.2 million**	Revenues:	**$6.2 million**
Earnings:	**$(662,000)**	Earnings:	**$482,000**
Cash on Hand:	**$856,000**	Cash on Hand:	**$1 million**
Debt:	**$42,000**	Debt:	**$285,000**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- 1Q19 (July 31, 2018 period end) 30% Core Revenue Growth and Transition to Profitability
- Record quarterly revenues of $6.2 million
- Operating margin of 7.9% versus –12.3% last year
- Earnings of $0.05 vs. estimates of ($0.02)
- Focusing on Adding Unique Tumors
- New Services Grow Total Addressable Market

KEY STATISTICS

Price as of 10/15/2018: **$12.65**
52 Week Range: **$3.04–17.90**
Market Cap: **140.78 million**
Shares O/S: **11.16 million**
Float (MM): **5.11 million**
Institutional Ownership %: **43.50**
Avg. Volume: **257,432**

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.

DAWSONJAMES SECURITIES Member FINRA/SIPC

2018 Small Cap Growth Conference

Company Name: **CHF Solutions Inc.**
Address: **12988 Valley View Road, Eden Prairie, MN 55344**
Exchange: **Nasdaq**
Symbol: **CHFS**

chf solutions

BUSINESS OVERVIEW

We are a medical device company focused on commercializing the Aquadex FlexFlow system for patients suffering from fluid overload. Our system is indicated for temporary ultrafiltration treatment of patients who have failed diuretic therapy, and extended ultrafiltration treatment of patients who have failed diuretic therapy and require hospitalization. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology.

MANAGEMENT

CEO:**John Erb**
CFO: **Claudia Napal Drayton**
Investor Relations Company Name: **Core IR**
Contact Person: **Bret Shapiro**
Email address: **brets@coreir.com**

Chairman: **John Erb**

Telephone Number: (**516) 222-2560**

Year Ending December 31, 2017 (FY)		Year to Date 2018 (June 30, 2018)	
Revenues:	**$ 3,553**	Revenues:	**$ 2,136**
Earnings:	**$ (13,382)**	Earnings:	**$ (8,535)**
Cash on Hand:	**$ 15,595**	Cash on Hand:	**$ 6,995**
Debt:	**$ 0**	Debt:	**$ 0**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- In early stages of commercialization; focused on heart failure market; recently announced additional focus on cardiac surgery market
- Recently expanded US sales team to 13 sales territories and 5 clinical specialists
- Double digit growth for 5 quarters
- Completed manufacturing transfer to in-house operations. Expect margin benefits in 2019
- $5.4M financing in July 2018

KEY STATISTICS

Price as of 10/15/2018: **$1.10**
52 Week Range: **$24.45**
Market Cap: **$8M**
Shares O/S: **7M**
Float (MM): **$7M**
Institutional Ownership %: **<5%**
Avg. Volume: **275,000**

DAWSONJAMES SECURITIES Member FINRA/SIPC

2018 Small Cap Growth Conference

Company Name: **Citius Pharmaceuticals, Inc.**
Address: **11 Commerce Dr. 1st Floor Cranford, NJ 07016**
Exchange: **Nasdaq**
Symbol: **CTXR**

CITIUS PHARMA

BUSINESS OVERVIEW

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. Citius is currently advancing two proprietary product candidates, our Mino-Lok® product and a hydrocortisone-lidocaine formulation. Citius believes the markets for its products are large and underserved by the current standard of care.

MANAGEMENT

President & CEO: **Myron Hobuliak**
CFO: **Jaime Bartushak**
Investor Relations Company Name: **IRTH Communications**
Contact Person: **Andrew Scott**
Email address: **ascott@citiuspharma.com**

Chairman: **Leonard Mazur**

Telephone Number: (**908) 967-6677, ext.105**

Year Ending September 30, 2017 (FY)		Year to Date, June 2018	
Revenues:	**$ 0**	Revenues:	**$ 0**
Earnings:	**$ (1.89)/share**	Earnings:	**$ (0.99)**
Cash on Hand:	**$ 3.2mm**	Cash on Hand:	**$ 2.8mm**
Debt:	**$ 200k**	Debt:	**$ 226k**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Large Market (>$1billion) with an unmet medical need
- Mino-Lok® has Q.I.D.P & Fast Track designation from FDA and study is currently in Phase 3
- Patent Protection until 2036
- Interim data analyses in Q2 2019
- Management has invested $18 million
- Raised $10 million in August 2018

KEY STATISTICS

Price as of 10/15/2018: **$1.68**
52 Week Range: **$5.49–$1.12**
Market Cap: **$29.2 million**
Shares O/S: **17,798,791**
Float (MM): **9,581,562**
Institutional Ownership %: **4%**
Avg. Volume: **239,000**

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: Cyclacel Pharmaceuticals, Inc.
Address: **200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922**
Exchange: **Nasdaq**
Symbol: **CYCC; CYCCP**

CYCLACEL®

BUSINESS OVERVIEW

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in cell cycle, transcriptional regulation and DNA damage response biology in cancer cells to develop innovative medicines. Cyclacel's transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced cancers. The DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers. CYC140, a Polo-like-kinase 1 (PLK-1) inhibitor, is ready to start investigation in cancer patients. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information, please visit www.cyclacel.com.

MANAGEMENT

CEO and President: **Spiro Rombotis**
CFO: **Paul McBarron**
Investor Relations Company Name: **RussoPartners LLC**
Contact Person: **Alex Fudukidis**
Email address: **alex.fudukidis@russopartnersllc.com**
Telephone Number: **(646) 942-5632**

Year Ending December 31, 2017 (FY)		Year to Date June 2018	
Revenues:	**$ NIL**	Revenues:	**$ NIL**
Earnings:	**$ (7.5) million**	Earnings:	**$ (3.2) million**
Cash on Hand:	**$ 23.9 million**	Cash on Hand:	**$ 19.8 million**
Debt:	**$ NIL**	Debt:	**$ NIL**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- CYC065 Ph1 data solid tumors at AACR 2018
- Announced strategic alliance MD Anderson Cancer Center to study 3 Cyclacel medicines in hematological malignancies
- Start CYC065 Ph1b comb. with venetoclax in CLL
- Start CYC140 (Plki) Ph1 first-in-human study
- Start sapacitabine + olaparib in BRCA +ve breast cancer
- Determine submissibility of sapacitabine in elderly AML

KEY STATISTICS

Price as of 10/15/2018: **$1.38**
52 week range: **$0.47–$2.13**
Shares O/S: **35.6m**
Float: **9.66m**
Institutional Ownership %: **5.69%**
Avg. Volume: **69.87K**

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **Daré Bioscience, Inc.**
Address: **3655 Nobel Drive, Suite 260, San Diego, CA 92122**
Exchange: **Nasdaq**
Symbol: **DARE**

darébioscience

BUSINESS OVERVIEW

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's reproductive and sexual health. The company's mission is to identify, develop and bring to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women in the areas of contraception, vaginal health, sexual health, and fertility.

Daré's product portfolio includes two potential first-in-class candidates currently in clinical development: Ovaprene®, a non-hormonal, monthly contraceptive vaginal ring, and Topical 5% Sildenafil Citrate Cream, a potential treatment for female sexual arousal disorder utilizing the same active ingredient as Viagra®. To learn more about Daré's full portfolio of women's health products, and mission to deliver novel therapies for women, please visit www.darebioscience.com.

Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré uses these channels to communicate with its investors and the public about the company and other issues. The information Daré posts on its investor relations website may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts on its investor relations website.

MANAGEMENT

CEO: **Sabrina Martucci Johnson**
Chairman: **Roger L. Hawley**
President: **Sabrina Martucci Johnson**
CFO: **Lisa Walters-Hoffert**
Other Officers: **David Friend** (CSO), **John Fair** (CBO)
Investor Relations Company Name: **Burns McClellan**
Contact Person: **Ami Bavishi**
Email address: **abavishi@burnsm.com**
Telephone Number: (**212) 213-0006**

Year Ending December 31, 2017 (FY)		Year to Date 2018	
Revenues:	**$ 0**	Revenues:	**$ 0**
Earnings:	**$ (11,521,197)**	Earnings:	**$ (11,302,157)**
Cash on Hand:	**$ 7,559,846**	Cash on Hand:	**$ 12,446,524**
Debt:	**$ 0**	Debt:	**$ 0**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- A pure play biopharmaceutical company focused on improving the health and well being of women.
- The portfolio is well positioned to drive upside value in the short and long term and each asset is positioned to be a first-in-category opportunity.
- Ovaprene PCT study read-out in 2019
- $10.25 m financing in Feb. 13

KEY STATISTICS

Price as of 10/15/2018: **$1.12**
52 Week Range: **$0.74–$3.59**
Market Cap: **$10.9m**
Shares O/S: **11.42m**
Float (MM): **8.13m**
Institutional Ownership %: **28.97%**
Avg. Volume: **221.29k**

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **Digerati Technologies, Inc.**
Address: **1600 NE Loop 410, Suite 126, San Antonio, Texas 78209**
Exchange: **OTCQB**
Symbol: **DTGI**

BUSINESS OVERVIEW

Digerati Technologies, Inc. (OTCQB: DTGI) is a provider of cloud services specializing in UCaaS (Unified Communications as a Service) solutions for the business market. Through its subsidiaries Synergy Telecom and T3 Communications, Inc. the Company is meeting the global needs of businesses seeking simple, flexible, reliable, and cost-effective communication and network solutions, including cloud PBX, cloud mobile, Internet broadband, SD-WAN, SIP trunking, and customized VoIP services, all delivered on its carrier-grade network and Only in the Cloud™.

MANAGEMENT

CEO: **Arthur L. Smith**
President: **Arthur L. Smith**
Investor Relations Company Name: **Hayden IR**
Contact Person: **Stephen Hart**
Email address: **hart@haydenir.com**

Chairman: **Craig K. Clement**
CFO: **Antonio Estrada Jr.**

Telephone Number: **(917) 658-7878**

Fiscal Year Ending July 31, 2017 (in thousands)		Fiscal Year Ending July 31, 2018 (pro forma, in thousands)	
Revenues:	**$ 193**	Revenues:	**$ 5,582**
Earnings (Loss):*	**$ (1,411)**	Earnings (Loss):**	**$ (2,084)**
Cash on Hand:	**$ 673**	Cash on Hand:	**$ 388**
Debt:	**$ 0**	Debt:	**$ 2,666**

** Net of stock & warrant expense of $733K and miscellaneous gain of $2,623K*

*** Net of Stock & warrant expense of $2,166K*

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- High-margin recurring revenue model
- 700+ customers under long-term contracts
- Proven management track record
- $26 billion market opportunity
- 58% organic revenue growth – YoY
- Growth via industry consolidation
- Solid acquisition pipeline

KEY STATISTICS

Price as of 10/15/2018: **$0.24**
52 Week Range: **$0.165–$0.80**
Market Cap: **$3,863,044**
Shares O/S: **12,876,815**
Float (MM): **5,761,023**
Institutional Ownership %: **0**
Avg. Volume: **8,371 per day**

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **Fennec Pharmaceuticals**
Address: **68 TW Alexander Drive, Research Triangle Park, NC 27709**
Exchanges: **Nasdaq; TSX**
Symbol: **FENC; FRX.TO**

BUSINESS OVERVIEW

Fennec Pharmaceuticals Inc. is a speciality pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients. Cisplatin, a widely used platinum based chemotherapy agent, can cause irreversible and permanent hearing loss in children. Fennec has completed two pediatric Phase III studies to evaluate the reduction in ototoxicity and impact on survival.

MANAGEMENT

CEO: **Rosty Rakov**
President: . . .

Investor Relations Contact Person: **Ryan Aldridge**
Email address: **raldridge@fennecpharma.com**

Chairman: **Dr. Khalid Islam**
CFO: **Robert Andrade**
Email: **randrade@fennecpharma.com**; Telephone: **919-246-5299**

Telephone Number: (**646) 771-0490**

Year Ending December 31, 2017 (FY)		Year to Date 2018	
Revenues:	**$ . . .**	Revenues:	**$ . . .**
Earnings:	**$ . . .**	Earnings:	**$ . . .**
Cash on Hand:	**$ 28.6M**	Cash on Hand: 6/30.18	**$ 25.6M**
Debt:	**$ 0**	Debt:	**$ 0**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- PFDD meeting September 2018
- NDA and MAA filing upcoming
- Pedmark Expected Approval 2019
- Last financing December 2017: 21M
- Cash balance of as June 30, 2018: $25.6M
- No debt

KEY STATISTICS

Price as of 10/15/2018: **$7.73**
52 Week Range: **$7.55–$14.99**
Market Cap: **~149M**
Shares O/S: **18.9M**
Float (MM): **10.7 million**
Institutional Ownership %: **~67%**
Avg. Volume: **~84,000**

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.

DAWSONJAMES SECURITIES *Member FINRA/SIPC*

2018 Small Cap Growth Conference

Company Name: **Finjan Holdings**
Address: **2000 University Ave, Suite 600, E. Palo Alto, CA.**
Exchange: **Nasdaq**
Symbol: FNJN

finjan® Cybersecurity

BUSINESS OVERVIEW

Established more than 20 years ago, Finjan is a globally recognized pioneer in cybersecurity. Finjan's inventions are embedded within a strong portfolio of patents focusing on software and hardware technologies capable of proactively detecting previously unknown and emerging threats on a real-time, behavior-based basis. Finjan continues to grow through investments in innovation, strategic acquisitions, and partnerships promoting economic advancement and job creation.

MANAGEMENT

CEO: **Phil Hartstein**
Chairman: **Daniel Chinn**
CIPO: **Julie Mar Spinola**
CFO: **Michael Noonan**
Investor Relations Company Name: **Finjan Holdings**
Contact Person: **Vanessa Winter**
Email address: **vanessa@finjan.com**
Telephone Number: (**650) 492-6537**

Year Ending December 31, 2017 (FY)		Year to Date 2018	
Revenues:	**$50.5**	Revenues:	**$83.2**
Earnings:	**$0.90**	Earnings:	**$1.31**
Cash on Hand:	**$41.2**	Cash on Hand:	**$65.0**
Debt:	**$0**	Debt:	**$0**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Fundamental and Comprehensive Cybersecurity Patent Portfolio
- Successful Licensing & Enforcement History
- Increasing Demand as Cybersecurity Market Expands
- Significant Financial Momentum
- Multiple Growth Opportunities
- Outstanding Management Team€

KEY STATISTICS

Price as of 10/15/2018: **$4.11**
52 Week Range: **$1.66–$5.07**
Market Cap: **$125.6M**
Shares O/S: **27.2M**
Float (MM): **16.3**
Institutional Ownership %: **64%**
Avg. Volume (3 month): **447,720**

DAWSONJAMES SECURITIES *Member FINRA/SIPC*

2018 Small Cap Growth Conference

Company Name: **GrowGeneration Corp.**
Address: **1000 West Mississippi Ave.**
Exchange: **OTCQX**
Symbol:

GrowGeneration WHERE THE PROS GO TO GROW

BUSINESS OVERVIEW

GrowGeneration is one of the largest retail hydroponic and organic specialty gardening retail outlets in the industry. Today, GrowGeneration owns and operates a chain of 19 retail hydroponic/gardening stores, with 6 located in the Colorado, 6 in California, 3 in Michigan, 1 in Nevada, 1 in Washington, 1 in Rhode Island and 1 in Oklahoma. GrowGeneration carries and sells thousands of products, including organic nutrients and soils, advanced lighting technology and state of the art hydroponic equipment to be used indoors and outdoors by commercial and home growers. Our plan is to open and operate hydroponic/gardening stores throughout the United States.

MANAGEMENT

CEO: **Darren Lampert**
Chairman: **Darren Lampert**
President: **Michael Salaman**
CFO: **Monty Lamirato**
COO: **Joe Prinzivalli**
Investor Relations Contact Person: **Brian Tantalo**
Email address: **brianptantalo@gmail.com**
Telephone Number: **(858) 353-9233**

Year Ending December 31, 2017 (FY)		Year to Date 2018 (June 30, 2018)	
Revenues:	**$ 14,364,000**	Revenues:	**$ 11,535,000**
Earnings:	**$ (2,543,000)**	Earnings:	**$ (1,883,000)**
Cash on Hand:	**$ 1,215,000**	Cash on Hand:	**$ 17,433,000**
Debt:	**$ 124,200**	Debt:	**$ 5,127,000**

KEY INVESTMENT CONSIDERATIONS / UPCOMING ILESTONES / MOST RECENT FINANCING

- $25 €n in acquisitions completed to date
- Our pipeline is deep and expanding
- GrowGen is the leading company in industry consolidation
- Acquisitions are accretive and present significant profit growth
- So far in 2018 we completed an equity private placement offering of $10 million, a convertible debt offering of $9 million and proceeds from the exercise of warrants and options of $2.6 million
- 2018 6-month revenue increased 74% y/y
- Sales increased 80% 2017 over 2016

KEY STATISTICS

Price as of 10/15/2018: **$4.39**
52 Week Range: **$1.75–$20.00**
Market Cap: **$114.6 millio**n
Shares O/S: **27.4 million**
Float (MM): **20.5 million**
Institutional Ownership %: **22%**
Avg. Volume **167,199**

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **Hemispherx Biopharma, Inc.**
Address: **2117 SW Highway 484, Ocala, FL 34773**
Exchange: **NYSE**
Symbol: **HEB**

HEMISPHERX® BIOPHARMA, INC. Advanced Therapies for the Human Immune System

BUSINESS OVERVIEW

Hemispherx Biopharma, Inc. is an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology. Hemispherx's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and a clinical trial, Hemispherx believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® already conducted by Hemispherx include studies of the potential treatment of cancer patients with renal cell carcinoma and malignant melanoma. These and other potential uses will require additional clinical trials to generate the safety and effectiveness data necessary to support regulatory approval.

MANAGEMENT

CEO: **Thomas K. Equels,** M.S. J.D.
CFO: **Adam Pascale**, CPA
Investor Relations Company Name: **LHA Investor Relations**
Contact Person: **Miriam Weber Miller**
Email address: **MMiller@lhai.com**

Chairman: **William M. Mitchell,** M.D., Ph.D.
Chief Scientific & Medical Officer: **David R. Strayer, M.D.**

Telephone Number: (**212) 838-3777**

Year Ending December 31, 2017 (FY)		Year to Date 2018 (as of 6/30/18)	
Revenues:	**$437,000**	Revenues:	**$89,000**
Net Loss:	**$(8,259,000)**	Net Loss:	**$(5,128,000)**
Cash and cash equivalents:	**$2,107,000**	Cash and cash equivalents:	**$4,242,000**
Note payable:	**$1,835,000**	Financing obligation arising from sale leaseback transaction — net of deferred costs:	**$2,612,000**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Hemispherx Biopharma is an immuno-pharma R&D and emerging commercial company focused on unmet medical needs in immunology.
- Primary pharmaceutical product platform consists of experimental compound Ampligen®, and FDA-approved natural interferon product Alferon N injection®.
- Ampligen (rintatolimod) (approved for ME/CFS in Argentina).
- A double-stranded RNA (nucleic acid) drug product administered intravenously being developed for the treatment of certain cancers and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS):
  - — Ampligen has a generally well-tolerated safety profile with approximately 100,000 IV doses in humans. No other TLR3 agonist has such a well-developed safety profile;
  - — Ampligen has a robust data package to support rapid development in immuno-oncology;
  - — Mechanism appears ideally suited to boost the efficacy of PD-1 and PD-L1 checkpoint inhibitors. Research collaborations underway at the University of Pittsburgh, Roswell Park Cancer Institute, and the University of Nebraska Medical Center;
  - — Pancreatic cancer therapeutic Program underway in Europe at Erasmus, MC;
  - — Successful Phase I/II studies in a variety of solid tumors, including ovarian, colorectal, renal cell carcinoma, and melanoma;
  - — Current studies exploring the safety and activity of promoting killer T cell accumulation in the tumor microenvironment of colorectal cancer.
- Alferon N Infection (interferon alfa-n3):
  - — Approved in U.S. and Argentina for refractory or recurrent external genital warts.

KEY STATISTICS

As of 10/8/18
Price as of 10/15/2018: **$0.21**
52 Week Range: **$0.15–$0.65**
Market Cap: **10.97 million**
Shares O/S: **47.75 million**
Float (MM): **46.14 million**
% Institutional Ownership: **6.67%**
Avg. Volume: **233,139**

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **IMV Inc.**
Address: **130 Eileen Stubbs, Suite 19, Dartmouth, Nova Scotia**
Exchange: **Nasdaq; TSX**
Symbol: **IMV**

IMV™

BUSINESS OVERVIEW

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Corporation's proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the reprogramming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently conducting eight phase 2 studies with Incyte and Merck assessing DPX-Survivac as a combination therapy in six different indications.

MANAGEMENT

CEO: **Frederic Ors**
CFO: **Pierre Labbé**
Investor Relations Company Name: **Westwicke Partners**
Contact Person: **Patti Bank**
Email address: **patti.bank@westwicke.com** Telephone Number: **(415) 513-1284**

Chairman: **Andrew Sheldon**
CMO: **Dr. Gabriela Rosu**

Year Ending December 31, 2017 (FY) (Canadian dollars)		Year to Date 2018 (June 30, 2018) (Canadian dollars)	
Revenues:	**$ 189,000**	Revenues:	**$ 226,000**
Loss:	**($ 12,028,000)**	Loss:	**($ 8,263,000)**
Cash on Hand:	**$ 14,909,000**	Cash on Hand:	**$ 25,148,000**
Debt:	**$ 6,476,000**	Debt:	**$ 6,977,000**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Top line Phase 1b/2 clinical results 300mg dose with Incyte in Ovarian . . . . End 2018
- Meeting with FDA on potential accelerated registration trial in Ovarian and/or DLBCL . . . . . End 2018
- Top line Phase 2 clinical results with Merck in DLBCL H1 2019
- Top line Phase 2 clin. results with Merck in Ovarian Q1 2019
- Preliminary clinical results Basket trial H1 2019
- Potential FDA accelerated/breakthrough designation registration trial in Ovarian and/or DLBCL. H1 2019
- Top line clinical results for Basket trial H2 2019
- Potential FDA accelerated/breakthrough designation from Basket trial Q4 2019
- Last financing: Feb 2018: $11MM US at $4.92/sh.

KEY STATISTICS

(USD)
Price as of 10/15/2018: **$5.35**
52 Week Range: **$2.75–$7.21**
Market Cap: **$254MM**
Shares O/S: **44.9MM**
Float (MM): **34.8MM**
Institutional Ownership %: **30%**
Avg. Volume (TSX+Nasdaq): **35,000**

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **Interpace Diagnostics**
Address: **300 Interpace Pkwy., Parsippany, NJ 07054**
Exchange: **Nasdaq**
Symbol: **IDXG**

INTERPACE DIAGNOSTICS

BUSINESS OVERVIEW

Interpace is a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company currently has four commercialized molecular tests and one test in a clinical evaluation process (CEP); PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX® (now ThyGeNEXT™) for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX™ that differentiates lung cancer of primary vs. metastatic origin. BarreGEN® for Barrett's Esophagus.

MANAGEMENT

CEO: **Jack E. Stover**
President: **Jack E. Stover**
Chief Commercial Officer: **Greg Richard**
Chairman: **Steve Sullivan**
CFO: **Jim Early**

Investor Relations Company Name: **Edison Group**
Contact Person: **Joe Green**
Email address: **jgreen@edisongroup.com**
Telephone Number: (**646) 653-7030**

Year Ending December 31, 2017 (FY)		Year to Date 2018 (June 30th)	
Revenues:	**$ 15.9 million**	Revenues:	**$ 10.3 million**
Earnings:	**$ (12.2) million**	Earnings:	**$ (5.1) million**
Cash on Hand:	**$ 15.2 million**	Cash on Hand:	**$ 10 million**
Debt:	**$ 0**	Debt:	**$ 0**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Expanding product opportunity in Barrett's Esophagus
- Growing reimbursement in all product categories
- Expanding our internal sales force
- Developing our bioinformatics prospects
- Announcing new supportive client data
- Driving cash flow breakeven

KEY STATISTICS

Price as of 10/15/2018: **$1.34**
52 Week Range: **$0.77–$1.80**
Market Cap: **$36.2 million**
Shares O/S: **28.6 million**
Float (MM): **28 million**
Shares held by insiders: **0.45%**
Institutional Ownership %: **16%**
Avg. Volume **706,500**

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **LiveXLive Media, Inc.**
Address: **9200 Sunset Blvd., Suite 1201, West Hollywood, CA 90069**
Exchange: **Nasdaq**
Symbol: **LIVX**

LIVEXLIVE PREMIUM LIVE MUSIC

BUSINESS OVERVIEW

LiveXLive Media, Inc. is a global digital media company dedicated to music and live entertainment. The company operates LiveXLive, one of the industry's leading live music streaming platforms; Slacker Radio, a streaming music pioneer; and also produces original music-related content. The LiveXLive platform delivers premium digital music experiences streamed live, through audio, and on-demand from the world's top music festivals and concerts, including Rock in Rio, EDC Las Vegas, Hangout Music Festival, and many more. LiveXLive also gives audiences access to premium original content, artist exclusives and industry interviews. Through its owned and operated Internet radio service, Slacker Radio, LiveXLive delivers its users access to millions of songs and hundreds of expert-curated stations. The company also operates a social influencer network, LiveXLive Influencers.

MANAGEMENT

CEO: **Rob Ellin**
President: **Phil Quartararo**
Chairman: **Rob Ellin**
CFO: **Mike Zemetra**

Investor Relations Company Name: **The Blueshirt Group**
Contact Person: **Alex Wellins**
Email address: **alex@blueshirtgroup.com**
Telephone Number: (**415) 217-5861**

Year Ending March 31, 2018 (FY)		Fiscal Year to Date 2018 (3/31/18 to 6/30/18)	
Revenues:	**$7.2M**	Revenues:	**$7.6M**
Earnings:	**$(0.48)**	Earnings:	**$(0.21)**
Cash on Hand:	**$8.8M**	Cash on Hand:	**$15.9M**
Debt:	**$3.5M**	Debt:	**$9.6M**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Company surpassed 35M Festival Livestreams in 4 months
- Exceeded 540,000 Paid Subscribers
- Produced and streamed 13 music festivals since May 17, 2018.
- Slacker monthly active users over 1M
- Streamed 300+ music artists across genres
- Aggregated more than 250 hours of live content, streamed via OTT and mobile devices globally.

KEY STATISTICS

Price as of 10/15/2018: **$2.86**
52 Week Range: **$2.64–$11.11**
Market Cap: **150.06M**
Shares O/S: **51.79M**
Float (MM): **23.28M**
Institutional Ownership %: **18.3%**
Avg. Volume **53.49K**

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **NanoVibronix**
Address: **525 Executive Blvd. Elmsford, NY 10523**
Exchange: **OTC /Nasdaq**
Symbol: **NAOV**

NANOVIBRONIX® Therapeutic Waves in Motion

BUSINESS OVERVIEW

Israeli medical device company incorporating its platform technology, "Surface Acoustic Wave," into it existing products addressing the Urology, Pain, and wound categories. All of the company's technologies are clinically validated by a vast body of research. Nasdaq listed, symbol NAOV.

MANAGEMENT

CEO: **Brian Murphy**
President: **William Stern**
Investor Relations Contact Person: **David Waldman**
Email address: **dwaldman@crescendo-ir.com**
Chairman: **Christopher Fashek**
CFO: **Stephen Brown**
Telephone Number: (**917) 355-2239**

Year Ending December 31, 2017 (FY)		Year to Date 2018	
Revenues:	**$500,000**	Revenues:	**$**
Earnings:	**$N/A**	Earnings:	**$**
Cash on Hand:	**$4,000,000**	Cash on Hand:	**$**
Debt:	**$0**	Debt:	**$**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Study results
- Distributors
- FDA clearance
- Manufacturing improvements
- Strategic alliances

KEY STATISTICS

Price as of 10/15/2018: $**4.26**
52 Week Range: $**4.20–$5.50**
Market Cap: **$30,000,000**
Shares O/S: **4,500,000**
Float (MM): **2.56 million**
Institutional Ownership %: **0**

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **OpGen, Inc.**
Address: **708 Quince Orchard Rd, Gaithersburg, MD 20878**
Exchange: **Nasdaq**
Symbol: **OPGN**

OpGen®

BUSINESS OVERVIEW

OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. For more information, please visit www.opgen.com.

MANAGEMENT

CEO: **Evan Jones**
CFO: **Timothy Dec**
Investor Relations Company Name: **LHA Investor Relations**
Contact Person: **Kim Golodetz**
Email address: **KGolodetz@lhai.com**
Chairman: **Evan Jones**
CIO: **Vadim Sapiro**
Telephone Number: (**212) 838-3777**

Year Ending December 31, 2017 (FY)		Year to Date 2018	
Revenues:	**$3.2 million**	Revenues:	**$1.6 million**
Net Loss:	**$15.4 million**	Net Loss:	**$6.4 million**
Cash on Hand:	**$1.8 million**	Cash on Hand:	**$7.4 million**
Debt:	**$1 million**	Debt:	**$1.3 million (at 6/30/18)**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Partnering with New York State Department of Health and Merck's ILÚM Health Solutions to Detect Antimicrobial-Resistant Infections
  - — $22.4 million New York State Life Sciences Initiative funding to partnership
  - — $1.5 million in development and test revenue during 2019
- Completed preliminary reviews with the FDA resulting in plans to file two 510(k) submissions for the Acuitas AMR Gene Panel u5.47, one for bacterial isolates and a second de novo submission for urine specimens and a separate de novo 510(k) submission for the Acuitas Lighthouse Software.
- Completed planning for the Acuitas AMR Gene Panel (Isolates) 510(k) FDA submission with testing of approximately 900 stock bacterial isolates and analytical validation testing of IUO product to begin during August.
- Achieved development milestone in CDC funded program for development of smartphone-based clinical decision support software with hospital testing underway in Colombia.
- Reported successful analytical validation and clinical verification results for the Acuitas AMR Gene Panel u5.47 (RUO)

KEY STATISTICS

As of 10-2-18
Price as of 10/15/2018: **$1.89**
52 Week Range: **$1.62–$10.25**
Market Cap: **12.3 million**
Shares O/S: **6.4 million**
Float (MM): **5.5 million**
% Institutional Ownership: **28.4%**
Avg. Volume: **99,593**

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **Opiant Pharmaceuticals Inc.**
Address: **201 Santa Monica Blvd., Suite 500, Santa Monica, CA 90401**
Exchange: **Nasdaq**
Symbol: **OPNT**

BUSINESS OVERVIEW

Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose. The National Institute on Drug Abuse, a component of the National Institutes of Health, describes addictive disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Opiant's first drug overdose product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by its commercialization partner, Adapt Pharmaceuticals.

MANAGEMENT

CEO: **Dr. Roger Crystal**
Lead Independent Director: **Dr. Gabrielle Silver**
President:
CFO: **David O'Toole**
Investor Relations Company Name: **LifeSci Advisors**
Contact Person: **Dan Ferry**
Email address: **Daniel@lifesciadvisors.com**
Telephone Number: **(617)-535-7746**

Year Ending December 31, 2017 (FY)		Year to Date 2018	
Revenues:	**$ 11.7**	Revenues:	**$ 4.9**
Earnings:	**$ N/A**	Earnings:	**$ N/A**
Cash on Hand:	**$ 8.1 Million**	Cash on Hand:	**$ 11.2 Million**
Debt:	**$ None**	Debt:	**$ None**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Our lead asset OPNT003 is a long-acting, rapid onset nalmefene nasal spray for opioid overdose reversal. 505(b)(2) development path to NDA filing in 2020. $7.4m NIH grant and BARDA contract for up to $4.6m, to complete development.
- OPNT001, a naloxone nasal spray, in Phase 2 for Bulimia Nervosa. Addressable market of $1B+ with little competition. Enrollment completed — top line results expected 1Q19.
- Emergent BioSolutions announced $735M purchase of Adapt. Highlights the value of NARCAN® and the potential value of our pipeline
- Annual royalty stream of approximately $20 million from net sales of NARCAN by commercial partner.
- Recently closed financing resulting in approx. $13m of gross proceeds, led by healthcare-focused institutional investors.

KEY STATISTICS

Price as of 10/15/2018: **$16.94**
52 Week Range: **$12.75–$48.00**
Market Cap: **$62 million**
Shares O/S: **3.8 million shares**
Float (MM): **2.26 million**
Institutional Ownership %: **15–20%**
Avg. Volume **56,000**

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **Orgenesis, Inc.**
Address: **20271 Goldenrod Lane, Germantown, MD 20876**
Exchange: **Nasdaq**
Symbol: **ORGS**

BUSINESS OVERVIEW

Orgenesis is a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and support services. Through its Israeli subsidiary, Orgenesis Ltd., Orgenesis is developing technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs). Orgenesis believes that converting the diabetic patient's own tissue into insulin-producing cells has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation. Through its Masthercell Global subsidiary, a global contract development and manufacturing organization (CDMO), Orgenesis is able to deliver optimized process industrialization capacities to cell therapy organizations and speed up the arrival of their therapies onto the market. From technology selection to business modeling, GMP manufacturing, process development, and quality management, Masthercell's teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. Masthercell operates in a validated and flexible facility located in the strategic center of Europe within the Walloon healthcare cluster, Biowin. This integrated approach supports the Company's business philosophy of bringing to market significant life-improving medical treatments.

MANAGEMENT

CEO: **Vered Caplan**
President: **Vered Caplan**
CFO: **Neil Reithinger**
CSO: **Sarah Ferber**
Investor Relations Company Name: Crescendo Communications
Contact Person: **David Waldman**
Email address: **dwaldman@crescendo-ir.com**
Telephone Number: (**917) 355-2239**

Year Ending November 31, 2017 (FY)		Year to Date 2018 (as of May 31)	
Revenues:	**$10,089,000**	Revenues:	**$ 3,987,000**
Earnings:	**$ 3,282,000**	Earnings:	**$1,792, 000**
Cash on Hand:	**$ 3,519,000**	Cash on Hand:	**$4,502,000**
Debt:	**$ 22,143,000**	Debt:	**$ 15,110,00**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Established position as a leading global CDMO
  - — Rapid revenue growth & world-class customer base
  - — High margin, scalable business model
  - — Major revenue partner with CDMO customers as they advance from clinical development to commercialization
  - — Each customer has the potential to generate billions of USD in cell manufacturing revenue
- Breakthrough platform technology for transdifferentiating adult cells
  - — First indication: potential "practical cure" for insulin dependent diabetes
  - — Ability to expand into additional indications
- Direct benefits of operating CDMO and developing proprietary platform include immediate cash flow to offset clinical costs, and guaranteed, long-term, low-cost internal manufacturing
- Strong IP portfolio with manufacturing expertise and EMA accreditation

KEY STATISTICS

As of 10/5/18
Price as of 10/15/2018: **$6.06**
52 Week Range: **2.7600–16.800**
Market Cap: **$103.88 MM**
Shares O/S: **14.57 M** (as of 7/16/18)
Float (MM): **12.79 million**
Institutional Ownership %: **10.75%**
Avg. Volume **62,665**

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.

DAWSONJAMES SECURITIES Member FINRA/SIPC

2018 Small Cap Growth Conference

Company Name: **PAVmed, Inc.**
Address: **One Grand Central Place, Suite 4600 New York, NY 10165**
Exchange: **Nasdaq**
Symbol: **PAVM**

PAVmed INNOVATING AT THE SPEED OF LIFE™

BUSINESS OVERVIEW

PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model designed to advance innovative products to commercialization much more rapidly and with significantly less capital than the typical medical device company. PAVmed's diversified pipeline of products address unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its four lead products provide groundbreaking approaches to carpal tunnel syndrome (CarpX™), precancerous conditions of the esophagus (EsoCheck™), vascular access (PortIO™) and pediatric ear infections (DisappEAR™).

MANAGEMENT

Chairman & CEO: **Dr. Lishan Aklog**
CFO: **Dennis McGrath**
Chief Medical Officer: **Brian deGuzman**
Chief Commercial Officer: **Shaun O'Neil**
Director of Investor Relations: **Mike Havrilla**
Email address: **JMH@PAVmed.com**
Telephone Number: (**814) 241-4138**

Year Ending December 31, 2017 (FY)		Year to Date 2018 (as of 6/30/18)	
Revenues:	**$0**	Revenues:	**$0**
Earnings:	**($10.4M) GAAP net loss**	Earnings:	**($7.9M) GAAP net loss**
Cash on Hand:	**$1.5M**	Cash on Hand:	**$11.1M**
Debt:	**$1.9M**	Debt:	**$2.75M**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Raised $9.2M in net cash proceeds from June 2018 rights offering
- CarpX: Push 510(k) clearance over finish line
- EsoCheck: Target 510(k) submission in Q4-2018 and CLIA certification in Q1-2019
- PortIO: Target completion of de novo animal study and IDE submission in Q4-2018, complete strategic partnership
- DisappEAR: Complete resorption study in animals for 2019 FDA 510(k) submission

KEY STATISTICS

As of market close on 9/28/18
Price as of 10/15/2018: **$1.14**
52 Week Range: **$0.87–$5.99**
Market Cap: **$34.5 million**
Shares O/S: **26.5 million**
Float (MM): **15.4 million**
Institutional Ownership: **6.7%**
Avg. Volume (50-day): **575,000**

DAWSONJAMES SECURITIES Member FINRA/SIPC

2018 Small Cap Growth Conference

Company Name: **Payment Data Systems**
Address: **12500 San Pedro, San Antonio, Tx 78216**
Exchange: **Nasdaq**
Symbol: **PYDS**

PAYMENT Data Systems

BUSINESS OVERVIEW

Payment Data Systems, Inc. provides integrated electronic payment processing services, such as automated clearing house (ACH) processing; and credit, prepaid card, and debit card-based processing services. Among its ACH processing services is Accounts Receivable Check Conversion, a consumer paper check payment, which is converted into an e-check. The company also offers merchant account services for the processing of card-based transactions through the VISA, MasterCard, American Express, and Discover networks, The company also creates, manages, and processes prepaid card programs for corporate clients to issue prepaid cards to their customer base or employees; and issues general purpose reloadable cards to consumers as an alternative to a traditional bank account. Payment Data Systems, Inc. was founded in 1998.

MANAGEMENT

CEO: **Louis Hoch**
Chief Revenue Officer: **Vaden Landers**
SVP of Prepaid Services: **Houston Frost**
Chairman: **Michael Long**
CFO: **Tom Jewell**
Investor Relations Company Name: Gregory Investor Relations
Contact Person: **Joe Hassett**
Email address: joeh@gregoryfca.com
Telephone Number: (**610) 228-2110**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Second Quarter (June)
  - — Revenues up 146%
  - — Highest volume of dollars processed
  - — Solid Financial Position – no debt
- August: University Fancards added as new prepaid card partnership
- Recognized by *CIO Review Magazine* as one of 20 Most Promising Payments Solutions Providers

KEY STATISTICS

Price as of 10/15/2018: **$1.71**
52 Week Range: **$1.35–$4.10**
Market Cap: **$30 MM**
Shares O/S: **16 MM**
Float (MM): **7.6 MM**
Institutional Ownership %: **>15%**
Avg. Volume: **45,000**

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.

Company Name: **Precision Therapeutics Inc.**
Address: **2915 Commers Drive, Suite 900, Eagan, MN 55121**
Exchange: **Nasdaq Capital**
Symbol: **AIPT**

BUSINESS OVERVIEW

Precision Therapeutics Inc. ("Precision Therapeutics" or "the Company") is a healthcare company that provides personalized medicine† solutions and medical devices in two main areas: (1) precision medicine, which aims to apply artificial intelligence (AI) to personalized medicine and drug discovery; and (2) Skyline Medical, which markets the FDA€cleared STREAMWAY® System for automated, direct€to€drain medical fluid waste collection and disposal. The Company's precision medicine services—designed to use AI and a comprehensive disease database to improve the effectiveness of cancer therapy—were launched with Precision Therapeutics' investment in Helomics® Corporation. Helomics' precision oncology services are based on its D€CHIP™ diagnostic platform, which combines a database of genomic and drug response profiles from over 149,000 tumors with an AI€based searchable bioinformatics platform.

MANAGEMENT

CEO: **Dr. Carl Schwartz**
President: **Dr. Carl Schwartz**
Investor Relations Company Name: **KCSA**
Contact Person: **Todd Fromer**
Email address: **tfromer@kcsa.com**
Chairman: **Thomas McGoldrick**
CFO: Bob Myers
Telephone Number: (**212) 682-6300**

Year Ending December 31, 2017 (FY)		Year to Date 2018	
Revenues:	**$ 655,000**	Revenues:	**$ 1,123,000**
Earnings:	**$ (7,8000,000)**	Earnings:	**$ (4,133,000)**
Cash on Hand:	**$ 1,000,000**	Cash on Hand:	**$ 850,000**
Debt:	**$ 0**	Debt:	**$ 0**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- €Merger with Helomics Corporation
- Artificial Intelligent D-CHIP Business
- Increasing CRO Business
- Increasing Medical Device Sales
- Expansion into European Markets – Med. Device
- New World Class Scientific Advisory Board

KEY STATISTICS

Price as of 10/15/2018: **$0.89**
52 Week Range: **$2.50–$0.81**
Market Cap: **$12,924,472**
Shares O/S: **$14,048,339**
Float (MM): **$13,900,000**
Institutional Ownership %: **2.64**
Avg. Volume **84,246**

2018 Small Cap Growth Conference

Company Name: **Sigma Labs Inc.**
Address: **3900 Paseo Del Sel, Santa Fe, NM 87507**
Exchange: **Nasdaq CM**
Symbol: **SGLB**

BUSINESS OVERVIEW

Sigma Labs is a provider of 3D printing product services including quality assurance software and contract 3D printing services to the Aerospace, Healthcare, Automotive and Consumer Products Industries.

MANAGEMENT

President, CEO & Chairman: **John Rice**
CTO: **Darren Beckett**
Investor Relations Company Name: **Core IR**
Contact Person: Bret Shapiro — **brets@coreir.com**
CFO: **Nannette Toups**
VP of Business Development: **Ron Fisher**
Telephone number: (**516) 479-8566**

Year Ending December 31, 2017 (FY)		Year to Date 2018 (1Q/2Q)	
Revenues:	**$ 641,000**	Revenues:	**$ 202,078**
Earnings:	**$ ($4,600,000)**	Earnings:	**$ ($2,559,680)**
Cash on Hand:	**$ 1,515,674**	Cash on Hand:	**$ 3,519,637**
Debt:	**$ 0**	Debt:	**$ 0**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Recently Demonstrated Proof of Concept Closed Loop
- Quality Control
- Completed $2-4 M Financing in 2Q 2018
- Released Version 3.0.2 of PrintRite 3D Inspection of Software
- Recently Contracted with Federally Funded Aerospace Organization to Streamline 3D Metal Manufacturing

€
€

KEY STATISTICS

Price as of 10/15/2018: **$1.14**
52 Week Range: **$0.73–$4.48**
Market Cap: **$10.8 M**
Shares O/S: **8.2 M**
Float (MM): **~ 6.34 M**
Institutional Ownership %: **N/A**
Avg. Volume: **94,745**

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **Sonoma Pharmaceuticals**
Address: **1129 N. McDowell Blvd. Petaluma, CA 94954**
Exchange: **Nasdaq**
Symbol: **SNOA**

BUSINESS OVERVIEW

Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com.

MANAGEMENT

CEO: **Jim Schutz**
CFO: **Bob Miller**
Chairman: **Jerry McLaughlin**
Investor Relations Contact Person: **Bob Miller, CFO**
Email address: **bmiller@sonomapharma.com**
Telephone Number: (**925) 787-6218**

Year Ending March 31, 2018 (FY)		Year to Date 2018	
Revenues:	**$16.658M**	Revenues:	**$** . . .
Earnings:	**($14M)**	Earnings:	**$** . . .
Cash on Hand:	**$10M**	Cash on Hand:	**$** . . .
Debt:	**$0**	Debt:	**$** . . .

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Total revenues increased by 30% from $12.8 million in fiscal year 2017 to $16.7 million in fiscal year 2018;
- Dermatology net revenue increased by 40% from $4.1 million in fiscal year 2017 to $5.8 million in fiscal year 2018;
- Number of dermatology prescriptions filled increased 40% from 52,563 in fiscal year 2017 to 73,667 in fiscal year 2018;
- Partnered with the largest pharmaceutical company in Brazil to sell our proprietary HOCl dermatology products in Brazil;
- Obtained four 510(k) clearances from the FDA for Loyon and to add antimicrobial language to several of our key products;
- Hired 13 additional sales representatives for our sales team which now totals 28 representatives and five managers; and
- Obtained several international approvals for our products, including in Brazil and the United Arab Emirates.

KEY STATISTICS

Price as of 10/15/2018: **$1.56**
52 Week Range: **$1.31–$5.92**
Market Cap:**$12M**
Shares O/S: **6.7M**
Float (MM): **5.58**
Institutional Ownership %: **20%**
Avg. Volume: **95,000**

Sonoma Pharmaceuticals did not present at the 2018 Conference

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **STRATA Skin Sciences, Inc.**
Address: **100 Lakeside Drive, Suite 100, Horsham PA 19044**
Exchange: **Nasdaq**
Symbol: **SSKN**

BUSINESS OVERVIEW

STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® excimer laser and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; and the STRATAPEN® MicroSystem, marketed specifically for the intended use of micropigmentation. STRATA's unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company's partner dermatology clinics.

MANAGEMENT

President & CEO: **Dr. Dolev Rafaeli**
CFO: **Matthew C. Hill**
Chairman: **Mr. Uri Geiger**
Investor Relations Company Name: **LifeSci Advisors, LLC**
Contact Person: **Jeremy Feffer**
Email address: **Jeremy@lifesciadvisors.com**
Telephone Number: (**212) 915-2568**

Year Ending December 31, 2017 (FY)		Year to Date 2018	
Revenues:	**$31,449**	Revenues:	**$13.999**
Earnings:	**($18,831)**	Earnings:	**($3.578)**
Cash on Hand:	**$4,069**	Cash on Hand:	**$14,445**
Debt:	**$10,597**	Debt:	**$7,372**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Large market opportunity with over 35M patients in U.S. alone
- Unique business model leverages direct-to-consumer advertising to send patients to its partner dermatology clinics
- Launching the New XTRAC S3 308nm Laser at the ASDS October
- Completion of Clinical Study for MMD Tip and First Commercial Account October
- Strategic Agreement with Large Private Equity Backed Group of Dermatology Clinics August
- FDA Granted 510(k) clearance for Multi Micro Dose Tip (MMD) for XTRAC 308nm August
- $17-Million Equity Financing led by Accelmed Growth Partners April

KEY STATISTICS

Price as of 10/15/2018: **$3.18**
52 Week Range: **$1.06–$3.88**
Market Cap: **$96.3M**
Shares O/S: **29.9M**
Float (MM): **16.7M**
Institutional Ownership %: **28.7**
Avg. Volume: **301,721**

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **Titan Medical Inc.**
Address: **1000 – 170 University Avenue, Toronto ON M5H 3B3**
Exchange: **Nasdaq**
Symbol: **TMDI**

TITAN MEDICAL

BUSINESS OVERVIEW

Titan is focused on the development and planned commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System for single-port (single incision) robotic surgery. The system is comprised of a surgeon-controlled patient cart that includes a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body. Titan intends to initially pursue focused surgical indications for the SPORT Surgical System, which may include one or more of gynecologic, urologic, colorectal or general abdominal procedures.

MANAGEMENT

President & CEO: **David McNally**
CFO: **Stephen Randall**
Investor Relations Company Name: **LHA**
Contact Person: **Karen Sutton Golodetz**
Email address: **kgolodetz@lhai.com**

Chairman: **John Barker**
Telephone Number: (**212) 838-3777**

Year Ending December 31, 2017 (FY)		Year to Date 2018 – June 30	
Revenues:	**$0.00**	Revenues:	**$0.00**
Earnings:	**$(33,586,984)**	Earnings:	**$(6,694,114)**
Cash on Hand:	**$28,668,927**	Cash on Hand:	**$26,404,682**
Debt:	**$0.00**	Debt:	**$0.00**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Multi-billion-dollar surgical robotics market with few competitors
- 45 single-port preclinical studies successfully performed with SPORT Surgical System prototypes in US and Europe
- Announced completion of development of core surgical skills simulation modules for workstation September 2018
- Design Freeze planned mid-year 2019
- Planned filing of FDA 510(k) application and technical file for CE Mark by end of Q4 2019, commercialization in 2020
- Obtained NASDAQ Listing June 2018, raised $19.2 million in August 2018

KEY STATISTICS

Price as of 10/15/2018: **$2.23**
52 Week Range: **$1.70–$7.75**
Market Cap: **$47.3 million**
Shares O/S: **21,675,849**
Float (MM): **approximately 21.4 million**
Institutional Ownership %: **pproximately 15%**
Avg. Volume **177,700**

DAWSONJAMES SECURITIES Member FINRA/SIPC — 2018 Small Cap Growth Conference

Company Name: **Tonix Pharmaceuticals**
Address: **509 Madison Avenue, Suite 306, New York, NY 10022**
Exchange: **Nasdaq**
Symbol: **TNXP**

TONIX PHARMACEUTICALS

BUSINESS OVERVIEW

Tonix Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate, Tonmya® or TNX-102 SL, which has received Breakthrough Therapy designation by the FDA, is in Phase 3 development for the treatment of PTSD. In addition, TNX-102 SL is being developed for the treatment of agitation in Alzheimer's disease under a separate IND to support a Phase 2, potential efficacy study.

MANAGEMENT

CEO: **Seth Lederman**, MD
CFO: **Bradley Saenger**
CMO: **Gregory Sullivan**
Investor Relations Company Name: **Westwicke Partners**
Contact Person: **Peter Vozzo**
Email address: **Peter.Vozzo@westwicke.com**

Chairman: **Seth Lederman**, MD
COO: **Jessica Morris**
Telephone Number: (**443) 213-0505**

Year Ending December 31, 2017 (FY)		Year to Date 2018	
Revenues:	**$0**	Revenues:	**$0**
Earnings:	**$(21.1)M**	Earnings:	**$(13.0)M**
Cash on Hand:	**$25.5M**	Cash on Hand:	**$16.7M**
Debt:	**$0**	Debt:	**$0**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Phase 3 Breakthrough Therapy development for PTSD including military related PTSD. Major unmet need; ~11 million Americans affected
- New indication in development for agitation in Alzheimer's disease with Fast Track designation
- Complementary day-time PTSD treatment in development
- Innovative vaccine in development to prevent Smallpox
- Opportunity to supply stockpiling requirement; short development path
- Studies in mice suggest improved safety profile

KEY STATISTICS

Price as of 10/15/2018: **$0.59**
52 Week Range: **$0.58–$5.11**
Market Cap: **$6.2M**
Shares O/S: **10.0M**
Float (MM): **8.0M**
Institutional Ownership %: **26.74%**
Avg. Volume: **927,556**

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.

Company Name: **WidePoint Corporation**
Address: **7926 Jones Branch Dr. Suite 520, McLean, VA 22102**
Exchange: **NYSE American**
Symbol: **WYY**

BUSINESS OVERVIEW

WidePoint Corporation (NYSE American: WYY) is a leading provider of technology-based management solutions, including telecom management, mobile management, access management and identity management. For more information, visit widepoint.com.

MANAGEMENT

CEO: **Jin Kang**
President: **Jin Kang**
CFO: **Kito Mussa**
Chief Sales and Marketing Officer (CSMO): **Jason Holloway**
Investor Relations Company Name: **Liolios**
Contact Person: **Matt Glover**
Email address: **matt@liolios.com**
Telephone Number: **(949) 574-3860**

Year Ending December 31, 2017 (FY)		Year to Date 2018	
Revenues:	**$ 76.5M**	Revenues:	**$ 37.6M ~ (6Mos)**
Earnings:	**$ (0.02) EPS**	Earnings:	**$ (0.01) EPS**
Cash on Hand:	**$ 6.5M ~**	Cash on Hand:	**$ 7M ~**
Debt:	**$ 0.00**	Debt:	**$ 0.00**

KEY INVESTMENT CONSIDERATIONS / UPCOMING MILESTONES / MOST RECENT FINANCING

- Q3 Earnings Call 11/14/18
- Four quarters of positive adjusted EBITDA
- Strong customer retention over the last 12 months.
- Press Release on $18.7M in contract awards
- Contract recompete DHS CWMS BPA Contract

KEY STATISTICS

Price as of 10/15/2018: **$0.49**
52 Week Range: **$0.40–$0.73**
Market Cap: **$42.8M**
Shares O/S: **83.1M ~**
Float (MM): **34.9M**
Institutional Ownership %: **23%**
Avg. Volume: **168.2K** (10-day average)

DAWSONJAMES SECURITIES Member FINRA/SIPC 2018 Small Cap Growth Conference

DAWSON JAMES SECURITIES DISCLAIMER

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC"). The Firm does not make a market in the securities of any of the presenting companies. The Firm may have received investment banking compensation from some of the presenting companies in the past and may seek compensation for investment banking services in the future from the presenting companies. The Firm has received other compensation from the subject company(s) in the last 12 months for services unrelated to the managing or co-managing of a public offering.

The Firm and/or its directors and employees may own securities of the presenting companies and may increase or decrease holdings in the future.

NOTES

The information included in this book has been prepared by each of the individual presenting companies. Dawson James does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Dawson James is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Dawson James soliciting any offers to buy or sell any security of any company.

NOTES

DAWSON JAMES SECURITIES INC.
Member FINRA/SIPC
1 N. Federal Highway, 5th Floor
Boca Raton, Florida 33432
561-391-5555
www.dawsonjames.com